
    
      In addition to the data collected in this study, historical data from 43 patients treated
      with placebo from the multicenter trial of sirolimus in LAM (MILES) study (NCT00414648) were
      down weighted to an effective sample size of 18 for comparison of FEV1 and FVC endpoints.
      Reference to the publication of the MILES study has been provided under "Result Publication".
    
  